iBio (IBIO) EBITDA (2010 - 2026)

iBio (IBIO) has reported EBITDA for 17 consecutive years, with -$11.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA fell 118.93% year-over-year to -$11.4 million in Q2 2026; TTM through Jun 2026 was -$35.1 million, a 88.91% decrease from a year earlier, with the FY2026 full-year figure at -$35.1 million, down 88.91% from the prior year.
• EBITDA was -$11.4 million for Q2 2026 at iBio, down from -$8.4 million in the prior quarter.
• Over five years, EBITDA peaked at -$3.4 million in Q2 2024 and troughed at -$11.4 million in Q2 2026.
• A 5-year average of -$6.5 million and a median of -$5.6 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 57.48% in 2023 and slumped 118.93% in 2026, its largest moves.
• Over 5 years, EBITDA stood at -$10.6 million in 2022, then surged by 57.48% to -$4.5 million in 2023, then climbed by 1.71% to -$4.4 million in 2024, then slumped by 113.74% to -$9.4 million in 2025, then slipped by 20.49% to -$11.4 million in 2026.
• The last three EBITDA figures came in at -$11.4 million (Q2 2026), -$8.4 million (Q1 2026), and -$9.4 million (Q4 2025), per Business Quant data.